Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to leucine-rich repeat containing 10B, refers to a non-protein-coding RNA that is transcribed in the opposite direction to the LRRC10B gene. While antisense RNAs can sometimes regulate the expression of their sense gene partners, there is no current evidence that this particular transcript is a recognized therapeutic target, nor is there established information about its function, role in disease, or interactions with drugs. The designation "novel transcript" generally indicates it has been computationally annotated or observed in RNA sequencing data, but not necessarily characterized functionally or therapeutically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to leucine-rich repeat containing 10B.